GlassScriptPhysician profile
Haydee M Knott
NPI 1285808691
$3,769.62
in general payments reported to CMS, 2019-2025
23 companies · $815 in 2025
The $815 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $646 · 2021: $534 · 2022: $258 · 2023: $204 · 2024: $287 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282 · Education: $24.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.73 |
| Education | $24.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,083.78 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $464.02 | 2019-2024 | Jublia |
| Lilly USA, LLC | $379.42 | 2020-2023 | Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $265.60 | 2024-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $256.95 | 2019-2020 | |
| Galderma Laboratories, L.P. | $252.74 | 2019-2025 | Nemluvio |
| Merz North America, INC. | $215.24 | 2021-2025 | Xeomin |
| Sun Pharmaceutical Industries INC. | $197.34 | 2020-2025 | |
| Genzyme Corporation | $108.01 | 2021 | |
| Janssen Biotech, INC. | $72.63 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $54.32 | 2020-2021 | |
| Dermira, INC. | $53.24 | 2019-2020 | |
| Biofrontera INC. | $52.02 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $51.25 | 2023-2025 | Otezla |
| Abbvie INC. | $47.78 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $41.40 | 2019-2024 | Klisyri |
| Leo Pharma INC. | $39.93 | 2021-2025 | Anzupgo |
| Allergan, INC. | $33.96 | 2021 | |
| Incyte Corporation | $25.45 | 2021 | |
| Revance Therapeutics, INC. | $21.40 | 2024 | Daxxify |
| Dusa Pharmaceuticals, INC. | $20.03 | 2019 | |
| Aclaris Therapeutics, INC. | $19.04 | 2019 | |
| Mission Pharmacal Company | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haydee Knott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.